Logo image of BGLC

BIONEXUS GENE LAB CORP (BGLC) Stock Overview

USA - NASDAQ:BGLC - US0906283066 - Common Stock

5.09 USD
-0.1 (-1.93%)
Last: 10/24/2025, 8:10:46 PM
5.13 USD
+0.04 (+0.79%)
Pre-Market: 10/27/2025, 6:24:50 AM

BGLC Key Statistics, Chart & Performance

Key Statistics
Market Cap9.16M
Revenue(TTM)9.55M
Net Income(TTM)-2940000
Shares1.80M
Float940.00K
52 Week High15.6
52 Week Low2.01
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.63
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2020-03-11
Sector
GICS SectorIndustrials
GICS IndustryTrading Companies & Distributors
GICS IndustryGroupCapital Goods


BGLC short term performance overview.The bars show the price performance of BGLC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

BGLC long term performance overview.The bars show the price performance of BGLC in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of BGLC is 5.09 USD. In the past month the price decreased by -9.91%. In the past year, price increased by 35.73%.

BIONEXUS GENE LAB CORP / BGLC Daily stock chart

BGLC Latest News, Press Relases and Analysis

BGLC Competitors/Peers

The largest stocks on the US markets in the "Trading Companies & Distributors" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
URI UNITED RENTALS INC 21.43 58.76B
FAST FASTENAL CO 40.07 49.22B
FERG FERGUSON ENTERPRISES INC 25.04 48.83B
GWW WW GRAINGER INC 24.57 46.32B
AER AERCAP HOLDINGS NV 9.97 21.24B
FTAI FTAI AVIATION LTD 45.04 18.66B
WSO.B WATSCO INC -CL B 29.09 15.38B
WSO WATSCO INC 27.78 14.69B
QXO QXO INC 114.94 12.39B
WCC WESCO INTERNATIONAL INC 18.28 10.97B
CNM CORE & MAIN INC-CLASS A 21.51 10.79B
AIT APPLIED INDUSTRIAL TECH INC 25.72 9.83B

About BGLC

Company Profile

BGLC logo image BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.

Company Info

BIONEXUS GENE LAB CORP

10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi

KUALA LUMPUR WILAYAH PERSEKUTUAN MY

Employees: 30

BGLC Company Website

BGLC Investor Relations

Phone: 13072416898

BIONEXUS GENE LAB CORP / BGLC FAQ

What does BGLC do?

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.


What is the current price of BGLC stock?

The current stock price of BGLC is 5.09 USD. The price decreased by -1.93% in the last trading session.


Does BIONEXUS GENE LAB CORP pay dividends?

BGLC does not pay a dividend.


What is the ChartMill technical and fundamental rating of BGLC stock?

BGLC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of BIONEXUS GENE LAB CORP (BGLC)?

BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.63).


What is the market capitalization of BGLC stock?

BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 9.16M USD. This makes BGLC a Nano Cap stock.


What is the ownership structure of BIONEXUS GENE LAB CORP (BGLC)?

You can find the ownership structure of BIONEXUS GENE LAB CORP (BGLC) on the Ownership tab.


BGLC Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to BGLC. When comparing the yearly performance of all stocks, BGLC is one of the better performing stocks in the market, outperforming 80.9% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BGLC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BGLC. While BGLC has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BGLC Financial Highlights

Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS decreased by -47.02% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.21%
ROE -39.1%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-409.09%
Sales Q2Q%14.45%
EPS 1Y (TTM)-47.02%
Revenue 1Y (TTM)4.01%

BGLC Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

BGLC Ownership

Ownership
Inst Owners0.53%
Ins Owners36.67%
Short Float %1.63%
Short Ratio0.13